Advisory Services Network’s Adicet Bio ACET Stock Holding History

Advisory Services Network’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20	Closed	-$256	–	1815
2025 Q3	$256	Buy	+20	New	+$236	﹤0.01%	4172

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Advisory Services Network's ACET Position: Q4 2025 in Review

Advisory Services Network sold out of Adicet Bio (ACET) in Q4 2025, closing a stake of 20 shares — an estimated $256 sold.

Advisory Services Network first reported a position in ACET in Q3 2025 and held it in 1 quarter. The position peaked at $256 in Q3 2025. 49 funds tracked by Wall St. Rank hold ACET as of Q4 2025.

Advisory Services Network reported no remaining Adicet Bio position as of Q4 2025 after selling out during the quarter.
Advisory Services Network sold 20 Adicet Bio shares in Q4 2025, an estimated $256.
Advisory Services Network first reported a position in Adicet Bio in Q3 2025 and held it in 1 quarter.
Advisory Services Network's Adicet Bio position peaked at $256 in Q3 2025.
49 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2025.

Based on Advisory Services Network's 13F filing for Q4 2025, filed 17 Feb 2026.